You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Vaccine firms Bharat Biotech, Serum Institute patch up after war of words

Adar Poonawalla and Krishna Ella issue joint statement saying they would work together to roll out Covid-19 vaccine

Topics
Bharat Biotech | Serum Institute of India | Coronavirus Vaccine

Sohini Das  |  Mumbai 

Adar Poonawalla, Krishna Ella
Bharat Biotech CMD Krishna Ella (left) and Serum Institute of India CEO Adar Poonawalla

After engaging in a war of words, the chiefs of two of India’s leading vaccine makers — and (SII) — called a truce on Tuesday and pledged to work together for a “smooth roll-out” of Covid-19 vaccines.

In a joint statement, Chairman and Managing Director Krishna Ella and SII Chief Executive Officer Adar Poonawalla said the more important task in front of them was to save the lives and livelihoods of populations in India and the world. “Vaccines are a global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest,” the statement read.

“Now that two Covid-19 vaccines have been issued EUA (emergency use authorisation) in India, the focus is on manufacturing, supply, and distribution...Both companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth roll-out of vaccines,” it said. Poonawalla had tweeted about releasing a joint statement earlier in the day, while put out the statement on its Twitter handle.

ALSO READ: Govt clears air on Bharat Biotech's vaccine, says relied on safety data

The Drugs Controller General of India (DCGI) on Sunday approved Oxford-AstraZeneca’s vaccine, manufactured by SII in India as Covishield, and Bharat Biotech’s Covaxin for restricted emergency use in the country. However, a group of experts questioned the approval process, triggering a war of words.

In a joint statement, Bharat Biotech CMD Krishna Ella and CEO Adar Poonawalla said the more important task in front of them is to save the lives and livelihood of populations in India and the world

While Poonawalla had told a television channel that there were only three vaccines in the world with proven efficacy (Pfizer, Moderna, and Oxford-AstraZeneca) and everything else had been proven safe “just like water”, Ella said if his firm had done trials like AstraZeneca, the drug regulator would have “shut down the company”.

ALSO READ: Govt ready to roll out vaccine within 10 days of emergency nod: Health secy

It is learnt that the government did not take the controversy lightly and a top official in New Delhi engaged in the process of monitoring vaccine roll-out called up the two firms, asking them to put up a face of solidarity in public.

On Monday, a visibly upset Ella had told the media that the approval was given to his vaccine candidate based on the “excellent” animal challenge study data and on the fact that it had showed safety in over 25000 people. In the backdrop of a mutated strain from the UK, Ella felt that his vaccine candidate would prove effective as it was based on an inactivated whole virus platform. As for data on the matter, he said he needed a week’s time.

He pointed out that how the clinical trial data was well published (across five journals), unlike his Indian peers, and felt that the inadvertent dosing error by (when a half and full dose was given to one subset of volunteers) raised major questions on determining the vaccine’s efficacy. Both the firms together would have at least 70 million doses of Covid-19 vaccines ready by February and would thus play a major role in the roll-out of the vaccine in India for essential services workers. “The fight and the controversy surrounding the approval were definitely denting the country’s image. Moreover, it would impact the public perception of the vaccine. The regulator should have also explained the rationale behind the approvals instead of reading out from a sheet,” a senior official in the government said.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, January 05 2021. 18:03 IST
RECOMMENDED FOR YOU